About Xspray Pharma

Company Description

Xspray Pharma AB (publ) is a pharmaceutical company with several product candidates in clinical development, the first XS004 dasatinib recently filed with the FDA. Xspray’s strategy is to improve the quality of life for cancer patients by launching improved PKI products with relevant medical benefits and cost effectiveness.

Xspray Pharma uses its innovative, patented RightSize™ technology to develop 505(b)(2) improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs), for the treatment of cancer. The segment is the second largest in oncology and where drug prices are very high.

Xspray Pharma applies a unique platform technology:

- Improves the solubility of the active ingredient
- Best-in-class for high dose strength for poorly soluble drugs
- Fully amorphous (non-infringing to many crystalline products patents)

Year founded

2003

Served area

Worldwide

Headquarters

Råsundavägen 12, 16967 Solna – Sweden

Shareholder information

Shares outstanding

22,680,408

IPO

Sept. 20, 2017

Stock exchange(s)

Nasdaq Stockholm

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.